Literature DB >> 8875330

Ocular mini-tablets for controlled release of timolol: evaluation in rabbits.

P Chetoni1, L Mariotti Bianchi, B Giannaccini, M F Saettone, U Conte, M E Sangalli.   

Abstract

Topical delivery of timolol by inserts or similar controlled-release devices may offer distinct advantages over administration by eyedrops. The purpose of this investigation was the evaluation in rabbits of ophthalmic inserts (denominated mini-tablets, MT) for sustained/controlled release of timolol maleate (TiM). The MTs (diameter 3.5 mm, thickness 1.5 mm, average TiM content 0.34 or 0.68 mg) were prepared by compressing appropriate mixtures of powders with a standard tabletting machine. A thin, rate-controlling membrane was applied over the devices by spraying aqueous dispersions of acrylic copolymers. A first series of different (uncoated and coated) MTs were tested for release of TiM to the lacrimal fluid, using commercial eyedrops (Timoptol 0.5%) as a reference standard. Two MTs (one of which was coated) and the same reference solution were then selected for an ocular absorption study. Analysis of TiM in the aqueous humor indicated that the coated MT was capable of maintaining low and steady levels of TiM for at least 19 h, while the other device, identical but uncoated, produced a prolonged-pulse effect lasting about 8 h. The apparent mean residence time (MRT) of TiM in the aqueous humor was 1.3 h for the reference solution, 3.2 h for the uncoated MT, and 5.7 h for the coated one. The present preliminary results point to the potential validity of coated mini-tablets as simple systems for controlled ocular delivery of timolol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875330     DOI: 10.1089/jop.1996.12.245

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  3 in total

1.  Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

Authors:  Erin Lavik; Markus H Kuehn; Andrew J Shoffstall; Kristyn Atkins; Alina V Dumitrescu; Young H Kwon
Journal:  J Ocul Pharmacol Ther       Date:  2016-11-11       Impact factor: 2.671

Review 2.  New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.

Authors:  Shyam S Bansal; Abhijeet Joshi; Arvind K Bansal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Formulation and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet.

Authors:  Seyed Alireza Mortazavi; Zahra Jafariazar; Yasaman Ghadjahani; Hoda Mahmoodi; Farzaneh Mehtarpour
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.